1. Home
  2. Directory
  3. Massachusetts
  4. Boston
  5. Radiology
  6. NPI Profile
  7. Prescriptions 1790719458

IRVING DAVID KAPLAN M.D.
Prescription History 1790719458
Radiology - Radiation Oncology in Boston, MA

NPI Status: Active since July 10, 2006

Contact Information

BIDMC-RADIATION THERAPY
330 BROOKLINE AVENUE
BOSTON, MA
ZIP 02215
Phone: (617) 667-2345

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for IRVING DAVID KAPLAN M.D., an active Radiation Oncology specialist practicing in Boston, MA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 251 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 138 claims alone.

Medication Index

N
O
T
X
No matching medications currently found on file.

Nubeqa

Generic Formulation: DarolutamideSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
MA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.0
Peer Average Days Supply957
Conservative Utilization

This provider writes prescriptions for this formulation 35.5% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $268,244.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,412.24

State Avg Cost Per Claim

$12,472.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Darolutamide is used to treat a certain type of prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Orgovyx

Generic Formulation: RelugolixSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 38
30-Day Fills 38.0
Days Supply 1,132
MA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.1
Peer Average Days Supply955
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $101,935.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,682.51

State Avg Cost Per Claim

$2,545.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Relugolix is used to treat prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.0
Days Supply 577
MA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills84.9
Peer Average Days Supply2,528
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $312.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.30

State Avg Cost Per Claim

$37.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 138
30-Day Fills 375.3
Days Supply 11,239
MA State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills163.8
Peer Average Days Supply4,817
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 86.5% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,716.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.18

State Avg Cost Per Claim

$24.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 41
30-Day Fills 43.0
Days Supply 1,290
MA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.6
Peer Average Days Supply885
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 41.4% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $623,054.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,196.45

State Avg Cost Per Claim

$12,726.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like IRVING DAVID KAPLAN M.D. provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.